Fig. 2.

Clinical activity of the VPC regimen. (A) Waterfall plot for the best percentage change in target lesion size (n = 26). (B) Spider plot showing individual patients and the time frame (n = 26). Tumor size is measured centrally as the sum of the longest diameters of the target lesions according to the RECIST 1.1 by independent radiology review for both (A) and (B). Only patients with at least one evaluable post-baseline target lesion scan (A and B) are included. Plots of the best percentage changes in the sum of the longest diameters of the target lesions are shown. Three patients had 0% change since baseline. Dashed lines at 30% decrease and 20% increase represent the cut-offs for identifying PR and PD, respectively, according to the RECIST 1.1. Abbreviations: VPC, vincristine, pegylated liposomal doxorubicin, and cyclophosphamide; RECIST, Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, disease progression.